J&J -in Study, at 5 Years, 67 Percent of Patients Were Progression-Free, With Overall Survival at 96 Percent for All Treated Patients
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.